Movesan (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene expression to suppress the release of inflammatory cytokines, inhibit leukocyte migration, and reduce vascular permeability. This results in a marked anti‑inflammatory and immunosuppressive effect at the site of application.

The appropriate dose of Movesan is determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated and patient age. Typical regimens involve applying a thin layer once or twice daily for a limited period, but exact instructions must come from the prescriber.

Safety data for topical mometasone furoate in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against possible risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Movesan with their physician.

To request Movesan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Movesan (mometasone furoate) is classified as a high‑potency topical corticosteroid, offering stronger anti‑inflammatory activity than low‑potency agents such as hydrocortisone. Compared with other high‑potency steroids like clobetasol propionate, mometasone provides a favorable balance of efficacy and a slightly lower risk of skin atrophy when used as directed.

Store Movesan at room temperature, preferably below 25 °C, in its original packaging. Protect the product from excessive moisture, direct sunlight and extreme temperatures. Keep the container tightly closed when not in use and out of reach of children.

Movesan should be applied to clean, dry skin. Use a fingertip‑sized amount to spread a thin, even layer over the affected area, gently rubbing it in until the film disappears. Follow the prescriber’s instructions regarding frequency and duration, and avoid covering the treated skin with occlusive dressings unless specifically advised.

Serious risks, though uncommon, include skin atrophy, telangiectasia, secondary bacterial or fungal infections, and systemic cortisol suppression, especially with prolonged or extensive use. Patients should report persistent thinning of the skin, unusual bruising, or signs of systemic steroid effects such as unexplained weight gain or mood changes.

Movesan should be avoided in individuals with known hypersensitivity to mometasone furoate or any excipients in the formulation. It is also contraindicated on severely infected, ulcerated or broken skin unless directed by a physician, and should be used with caution in patients with uncontrolled diabetes, glaucoma, or viral skin infections.